BEIGENE,LTD. (NASDAQ:BGNE) Files An 8-K Other Events
Item 8.01 Other Events.
On March9, 2017, BeiGene,Ltd. (the Company) issued a press
release announcing the dosing of the first patient in a pivotal
clinical trial of BGB-3111, an investigational Brutons Tyrosine
Kinase inhibitor, designed to investigate the efficacy and safety
of BGB-3111 in Chinese patients with relapsed or refractory
chronic lymphocytic leukemia or small lymphocytic lymphoma.The
full text of the Companys press release is filed as Exhibit99.1
to this Current Report on Form8-K and is incorporated herein by
reference.
Item9.01 Financial Statements and
Exhibits.
(d) Exhibits.
|
ExhibitNo. |
|
Description |
|
99.1 |
Press Release issued on March9, 2017 |
About BEIGENE, LTD. (NASDAQ:BGNE)
BeiGene, Ltd. is a biopharmaceutical company. The Company is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. It is developing its product candidate, BGB-3111, a potent and selective small molecule Bruton’s tyrosine kinase (BTK) inhibitor, as a monotherapy and in combination with other therapies for the treatment of a range of lymphomas. It is developing its product candidate, BGB-A317, a humanized monoclonal antibody against the immune checkpoint receptor programmed cell death protein 1 (PD-1), as a monotherapy and as a combination agent for various solid-organ and blood-borne cancers. It is developing BGB-290, a molecularly targeted, orally available, potent and selective inhibitor of poly ADP ribose polymerase 1 (PARP1) and PARP2, as a monotherapy and in combination with other therapies for the treatment of homologous recombination deficient cancers. It is also developing BGB-283 for the treatment of cancers. BEIGENE, LTD. (NASDAQ:BGNE) Recent Trading Information
BEIGENE, LTD. (NASDAQ:BGNE) closed its last trading session down -0.24 at 39.64 with 52,333 shares trading hands.